Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product

Dul, Maria ORCID: https://orcid.org/0000-0002-0192-2280, Alali, Mohammed, Ameri, Mahmoud, Burke, Matthew Douglas, Craig, Christine M., Creelman, Benjamin Paul, Dick, Lisa, Donnelly, Ryan F., Eakins, Michael N., Frivold, Collrane, Forster, Angus Harry, Gilbert, Philippe-Alexandre, Henke, Stefan, Henry, Sebastien, Hunt, Desmond, Lewis, Hayley, Maibach, Howard I., Mistilis, Jessica Joyce, Park, Jung-Hwan, Prausnitz, Mark R., Robinson, David Kenneth, Hernandez, Carmen Amelia Rodriguez, Ross, Charles, Shin, Juyeop, Speaker, Tycho Joseph, Taylor, Kevin Michael, Zehrung, Darin, Birchall, James C. ORCID: https://orcid.org/0000-0001-8521-6924, Jarrahian, Courtney and Coulman, Sion A. ORCID: https://orcid.org/0000-0002-1277-7584 2023. Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product. Journal of Controlled Release 361 , pp. 236-245. 10.1016/j.jconrel.2023.07.001

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Microneedle Array Patches (MAPs) are an emerging dosage form that creates transient micron-sized disruptions in the outermost physical skin barrier, the stratum corneum, to facilitate delivery of active pharmaceutical ingredients to the underlying tissue. Numerous MAP products are proposed and there is significant clinical potential in priority areas such as vaccination. However, since their inception scientists have hypothesized about the risk of a clinically significant MAP-induced infection. Safety data from two major Phase 3 clinical trials involving hundreds of participants, who in total received tens of thousands of MAP applications, does not identify any clinically significant infections. However, the incumbent data set is not extensive enough to make definitive generalizable conclusions. A comprehensive assessment of the infection risk is therefore advised for MAP products, and this should be informed by clinical and pre-clinical data, theoretical analysis and informed opinions. In this article, a group of key stakeholders identify some of the key product- and patient-specific factors that may contribute to the risk of infection from a MAP product and provide expert opinions in the context of guidance from regulatory authorities. Considerations that are particularly pertinent to the MAP dosage form include the specifications of the finished product (e.g. microbial specification), it's design features, the setting for administration, the skill of the administrator, the anatomical application site, the target population and the clinical context. These factors, and others discussed in this article, provide a platform for the development of MAP risk assessments and a stimulus for early and open dialogue between developers, regulatory authorities and other key stakeholders, to expedite and promote development of safe and effective MAP products.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Elsevier
ISSN:	0168-3659
Date of First Compliant Deposit:	30 August 2023
Date of Acceptance:	1 July 2023
Last Modified:	20 Oct 2023 15:42
URI:	https://orca.cardiff.ac.uk/id/eprint/162107

Actions (repository staff only)

Edit Item